DE60307856D1 - Antitumorverbindung und ihre therapeutischen verwendungen - Google Patents

Antitumorverbindung und ihre therapeutischen verwendungen

Info

Publication number
DE60307856D1
DE60307856D1 DE60307856T DE60307856T DE60307856D1 DE 60307856 D1 DE60307856 D1 DE 60307856D1 DE 60307856 T DE60307856 T DE 60307856T DE 60307856 T DE60307856 T DE 60307856T DE 60307856 D1 DE60307856 D1 DE 60307856D1
Authority
DE
Germany
Prior art keywords
antitumoric
connection
therapeutic uses
fgf
men2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60307856T
Other languages
English (en)
Other versions
DE60307856T2 (de
Inventor
Cinzia Lanzi
Giuliana Cassinelli
Giuditta Cuccuru
Alessandro Pierotti
Franco Zunino
Ernesto Menta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto Nazionale per lo Studio e la Cura die Tumori
Cell Therapeutics Europe SRL
Original Assignee
Istituto Nazionale per lo Studio e la Cura die Tumori
Cell Therapeutics Europe SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Nazionale per lo Studio e la Cura die Tumori, Cell Therapeutics Europe SRL filed Critical Istituto Nazionale per lo Studio e la Cura die Tumori
Application granted granted Critical
Publication of DE60307856D1 publication Critical patent/DE60307856D1/de
Publication of DE60307856T2 publication Critical patent/DE60307856T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
DE60307856T 2002-07-23 2003-07-22 Antitumorverbindung und ihre therapeutischen verwendungen Expired - Lifetime DE60307856T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT2002MI001620A ITMI20021620A1 (it) 2002-07-23 2002-07-23 Composto ad ativita' antitumorale
ITMI20021620 2002-07-23
PCT/EP2003/007963 WO2004009083A1 (en) 2002-07-23 2003-07-22 Antitumor compound and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
DE60307856D1 true DE60307856D1 (de) 2006-10-05
DE60307856T2 DE60307856T2 (de) 2007-04-12

Family

ID=30130912

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60307856T Expired - Lifetime DE60307856T2 (de) 2002-07-23 2003-07-22 Antitumorverbindung und ihre therapeutischen verwendungen

Country Status (12)

Country Link
US (2) US20060258731A1 (de)
EP (1) EP1534271B1 (de)
JP (1) JP2005537277A (de)
CN (1) CN1668298A (de)
AT (1) ATE337001T1 (de)
AU (1) AU2003251437A1 (de)
CA (1) CA2493202A1 (de)
DE (1) DE60307856T2 (de)
ES (1) ES2271649T3 (de)
IT (1) ITMI20021620A1 (de)
MX (1) MXPA05000781A (de)
WO (1) WO2004009083A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005068424A1 (en) * 2004-01-20 2005-07-28 Cell Therapeutics Europe S.R.L. Indolinone derivatives as receptor tyrosine kinase ihibitors
WO2006119148A2 (en) * 2005-04-29 2006-11-09 The Ohio State University Research Foundation Keratinocyte growth factor receptor - tyrosine specific inhibitors for the prevention of cancer metastatis
BRPI0716555A2 (pt) * 2006-09-07 2013-09-24 Astrazeneca Ab mÉtodos para prever a probabilidade de que um paciente É um candidato para tratamento com uma droga de ret responderÁ ao citado tratamento, e para tratar um paciente, iniciador direto mutante de arms, e, kit diagnàstico
CA2952692C (en) 2008-09-22 2020-04-28 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
PL3699181T3 (pl) 2014-11-16 2023-05-22 Array Biopharma, Inc. Postać krystaliczna wodorosiarczanu (s)-n-(5-((r)-2-(2,5-difluorofenylo) - pirolidyn-1-ylo)-pirazolo[1,5-a]pirimidyn-3-ylo)-3-hydroksypirolidyno-1-karboksyamidu
MX2018000577A (es) 2015-07-16 2018-09-05 Array Biopharma Inc Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la ret quinasa.
SG11201803438XA (en) 2015-10-26 2018-05-30 Univ Colorado Regents Point mutations in trk inhibitor-resistant cancer and methods relating to the same
KR20180129911A (ko) 2016-04-04 2018-12-05 록쏘 온콜로지, 인코포레이티드 소아암을 치료하는 방법
SG11201808559PA (en) 2016-04-04 2018-10-30 Loxo Oncology Inc Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
JP7443057B2 (ja) 2016-05-18 2024-03-05 ロクソ オンコロジー， インコーポレイテッド （Ｓ）－Ｎ－（５－（（Ｒ）－２－（２，５－ジフルオロフェニル）ピロリジン－１－イル）－ピラゾロ［１，５－ａ］ピリミジン－３－イル）－３－ヒドロキシピロリジン－１－カルボキサミドの調製
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
EP3571203B1 (de) 2017-01-18 2023-06-07 Array BioPharma Inc. Substituierte pyrazolo[1,5-a]pyrazin verbindungen als ret kinase inhibitoren
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
JP7061195B2 (ja) 2018-01-18 2022-04-27 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［３，４－ｄ］ピリミジン化合物
CN111971286B (zh) 2018-01-18 2023-04-14 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
WO2020055672A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5502072A (en) * 1993-11-26 1996-03-26 Pfizer Inc. Substituted oxindoles
US6147106A (en) * 1997-08-20 2000-11-14 Sugen, Inc. Indolinone combinatorial libraries and related products and methods for the treatment of disease
US6130238A (en) * 1997-06-20 2000-10-10 Sugen, Inc. 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6133305A (en) * 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
NZ520640A (en) * 2000-02-15 2005-04-29 Upjohn Co Pyrrole substituted 2-indolinone protein kinase inhibitors

Also Published As

Publication number Publication date
CA2493202A1 (en) 2004-01-29
EP1534271A1 (de) 2005-06-01
JP2005537277A (ja) 2005-12-08
US20060258731A1 (en) 2006-11-16
DE60307856T2 (de) 2007-04-12
MXPA05000781A (es) 2005-09-21
AU2003251437A8 (en) 2004-02-09
ITMI20021620A1 (it) 2004-01-23
EP1534271B1 (de) 2006-08-23
WO2004009083A8 (en) 2005-02-03
WO2004009083A1 (en) 2004-01-29
ATE337001T1 (de) 2006-09-15
AU2003251437A1 (en) 2004-02-09
ES2271649T3 (es) 2007-04-16
US20090130229A1 (en) 2009-05-21
CN1668298A (zh) 2005-09-14

Similar Documents

Publication Publication Date Title
DE60307856D1 (de) Antitumorverbindung und ihre therapeutischen verwendungen
NO20050636L (no) Inhibitorer av tyrosinkinaser
NO20014560L (no) Quinasoliner og terapautisk anvendelse derav
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
EE05481B1 (et) Kinasoliini derivaadid kasvajate raviks
DE60214703D1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
DE60218458D1 (de) Isochinolinon derivate als parp inhibitoren
IL166625A0 (en) Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
AP1718A (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
DK1446012T3 (da) Bakteriolytisk kombinationsterapi til behandling af tumorer
NO20052760D0 (no) Fremgangsmate for behandling av kreft og beslektede fremgangsmater.
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
NO20035349D0 (no) Fotodynamisk terapilampe
NO20061322L (no) Kinazolinderivater som tyrosin kinase inhibitorer
ATE302771T1 (de) Indolinon-derivative als protein-kinasehemmer
DE60321808D1 (de) Flavon derivate als inhibitoren von cyclin-abhängigen kinasen
NO20040516L (no) Kombinasjonsterapi for behandling av kreft.
DE602004011924D1 (de) Chinazoline derivate und ihre anwendung in der krebsbehandlung
IS2568B (is) Kínasólínafleiður sem SRC týrósínkínasatálmar
DK1325011T3 (da) Fremgangsmåder og forbindelser til behandling af proliferative sygdomme
NO20055449D0 (no) Fremgangsmate for diagnostisering av behandling av kreft
ATE336489T1 (de) Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren
DE60305053D1 (de) Pyrimidinderivate als selektive cox-2-inhibitoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition